2023-09-012024-08-312024-08-31false14327842EPHARMA LIMITED2024-12-10falseiso4217:GBPxbrli:pure143278422023-09-01143278422024-08-31143278422023-09-012024-08-31143278422022-08-31143278422023-08-31143278422022-08-312023-08-3114327842bus:SmallEntities2023-09-012024-08-3114327842bus:AuditExempt-NoAccountantsReport2023-09-012024-08-3114327842bus:FullAccounts2023-09-012024-08-3114327842bus:PrivateLimitedCompanyLtd2023-09-012024-08-3114327842core:WithinOneYear2024-08-3114327842core:AfterOneYear2024-08-3114327842core:WithinOneYear2023-08-3114327842core:AfterOneYear2023-08-3114327842core:ShareCapital2024-08-3114327842core:SharePremium2024-08-3114327842core:RevaluationReserve2024-08-3114327842core:OtherReservesSubtotal2024-08-3114327842core:RetainedEarningsAccumulatedLosses2024-08-3114327842core:ShareCapital2023-08-3114327842core:SharePremium2023-08-3114327842core:RevaluationReserve2023-08-3114327842core:OtherReservesSubtotal2023-08-3114327842core:RetainedEarningsAccumulatedLosses2023-08-3114327842core:LandBuildings2024-08-3114327842core:PlantMachinery2024-08-3114327842core:Vehicles2024-08-3114327842core:FurnitureFittings2024-08-3114327842core:OfficeEquipment2024-08-3114327842core:NetGoodwill2024-08-3114327842core:IntangibleAssetsOtherThanGoodwill2024-08-3114327842core:ListedExchangeTraded2024-08-3114327842core:UnlistedNon-exchangeTraded2024-08-3114327842core:LandBuildings2023-08-3114327842core:PlantMachinery2023-08-3114327842core:Vehicles2023-08-3114327842core:FurnitureFittings2023-08-3114327842core:OfficeEquipment2023-08-3114327842core:NetGoodwill2023-08-3114327842core:IntangibleAssetsOtherThanGoodwill2023-08-3114327842core:ListedExchangeTraded2023-08-3114327842core:UnlistedNon-exchangeTraded2023-08-3114327842core:LandBuildings2023-09-012024-08-3114327842core:PlantMachinery2023-09-012024-08-3114327842core:Vehicles2023-09-012024-08-3114327842core:FurnitureFittings2023-09-012024-08-3114327842core:OfficeEquipment2023-09-012024-08-3114327842core:NetGoodwill2023-09-012024-08-3114327842core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3114327842core:ListedExchangeTraded2023-09-012024-08-3114327842core:UnlistedNon-exchangeTraded2023-09-012024-08-3114327842core:MoreThanFiveYears2023-09-012024-08-3114327842core:Non-currentFinancialInstruments2024-08-3114327842core:Non-currentFinancialInstruments2023-08-3114327842dpl:CostSales2023-09-012024-08-3114327842dpl:DistributionCosts2023-09-012024-08-3114327842core:LandBuildings2023-09-012024-08-3114327842core:PlantMachinery2023-09-012024-08-3114327842core:Vehicles2023-09-012024-08-3114327842core:FurnitureFittings2023-09-012024-08-3114327842core:OfficeEquipment2023-09-012024-08-3114327842dpl:AdministrativeExpenses2023-09-012024-08-3114327842core:NetGoodwill2023-09-012024-08-3114327842core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3114327842dpl:GroupUndertakings2023-09-012024-08-3114327842dpl:ParticipatingInterests2023-09-012024-08-3114327842dpl:GroupUndertakingscore:ListedExchangeTraded2023-09-012024-08-3114327842core:ListedExchangeTraded2023-09-012024-08-3114327842dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-09-012024-08-3114327842core:UnlistedNon-exchangeTraded2023-09-012024-08-3114327842dpl:CostSales2022-08-312023-08-3114327842dpl:DistributionCosts2022-08-312023-08-3114327842core:LandBuildings2022-08-312023-08-3114327842core:PlantMachinery2022-08-312023-08-3114327842core:Vehicles2022-08-312023-08-3114327842core:FurnitureFittings2022-08-312023-08-3114327842core:OfficeEquipment2022-08-312023-08-3114327842dpl:AdministrativeExpenses2022-08-312023-08-3114327842core:NetGoodwill2022-08-312023-08-3114327842core:IntangibleAssetsOtherThanGoodwill2022-08-312023-08-3114327842dpl:GroupUndertakings2022-08-312023-08-3114327842dpl:ParticipatingInterests2022-08-312023-08-3114327842dpl:GroupUndertakingscore:ListedExchangeTraded2022-08-312023-08-3114327842core:ListedExchangeTraded2022-08-312023-08-3114327842dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-08-312023-08-3114327842core:UnlistedNon-exchangeTraded2022-08-312023-08-3114327842core:NetGoodwill2024-08-3114327842core:IntangibleAssetsOtherThanGoodwill2024-08-3114327842core:LandBuildings2024-08-3114327842core:PlantMachinery2024-08-3114327842core:Vehicles2024-08-3114327842core:FurnitureFittings2024-08-3114327842core:OfficeEquipment2024-08-3114327842core:AfterOneYear2024-08-3114327842core:WithinOneYear2024-08-3114327842core:ListedExchangeTraded2024-08-3114327842core:UnlistedNon-exchangeTraded2024-08-3114327842core:ShareCapital2024-08-3114327842core:SharePremium2024-08-3114327842core:RevaluationReserve2024-08-3114327842core:OtherReservesSubtotal2024-08-3114327842core:RetainedEarningsAccumulatedLosses2024-08-3114327842core:NetGoodwill2023-08-3114327842core:IntangibleAssetsOtherThanGoodwill2023-08-3114327842core:LandBuildings2023-08-3114327842core:PlantMachinery2023-08-3114327842core:Vehicles2023-08-3114327842core:FurnitureFittings2023-08-3114327842core:OfficeEquipment2023-08-3114327842core:AfterOneYear2023-08-3114327842core:WithinOneYear2023-08-3114327842core:ListedExchangeTraded2023-08-3114327842core:UnlistedNon-exchangeTraded2023-08-3114327842core:ShareCapital2023-08-3114327842core:SharePremium2023-08-3114327842core:RevaluationReserve2023-08-3114327842core:OtherReservesSubtotal2023-08-3114327842core:RetainedEarningsAccumulatedLosses2023-08-3114327842core:NetGoodwill2022-08-3114327842core:IntangibleAssetsOtherThanGoodwill2022-08-3114327842core:LandBuildings2022-08-3114327842core:PlantMachinery2022-08-3114327842core:Vehicles2022-08-3114327842core:FurnitureFittings2022-08-3114327842core:OfficeEquipment2022-08-3114327842core:AfterOneYear2022-08-3114327842core:WithinOneYear2022-08-3114327842core:ListedExchangeTraded2022-08-3114327842core:UnlistedNon-exchangeTraded2022-08-3114327842core:ShareCapital2022-08-3114327842core:SharePremium2022-08-3114327842core:RevaluationReserve2022-08-3114327842core:OtherReservesSubtotal2022-08-3114327842core:RetainedEarningsAccumulatedLosses2022-08-3114327842core:AfterOneYear2023-09-012024-08-3114327842core:WithinOneYear2023-09-012024-08-3114327842core:Non-currentFinancialInstrumentscore:CostValuation2023-09-012024-08-3114327842core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-09-012024-08-3114327842core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-09-012024-08-3114327842core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-09-012024-08-3114327842core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-09-012024-08-3114327842core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-09-012024-08-3114327842core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3114327842core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3114327842core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3114327842core:Non-currentFinancialInstrumentscore:CostValuation2024-08-3114327842core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-08-3114327842core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-08-3114327842core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-08-3114327842core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-08-3114327842core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-08-3114327842core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-08-3114327842core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-08-3114327842core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-08-3114327842core:Non-currentFinancialInstrumentscore:CostValuation2023-08-3114327842core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-08-3114327842core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-08-3114327842core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-08-3114327842core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-08-3114327842core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-08-3114327842core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-08-3114327842core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-08-3114327842core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-08-3114327842bus:Director12023-09-012024-08-3114327842bus:Director22023-09-012024-08-3114327842core:FurnitureFittingsToolsEquipment2023-09-012024-08-3114327842core:FurnitureFittingsToolsEquipment2024-08-3114327842core:FurnitureFittingsToolsEquipment2023-08-31

EPHARMA LIMITED

Registered Number
14327842
(England and Wales)

Unaudited Financial Statements for the Year ended
31 August 2024

EPHARMA LIMITED
Company Information
for the year from 1 September 2023 to 31 August 2024

Directors

CHEEMA, Gurinder Singh
GILLANI, Kubra

Registered Address

32 Sandford Rise
Wolverhampton
WV6 9JQ

Registered Number

14327842 (England and Wales)
EPHARMA LIMITED
Statement of Financial Position
31 August 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets38,865-
8,865-
Current assets
Stocks412,115-
Debtors552,122100
Cash at bank and on hand24,609-
88,846100
Creditors amounts falling due within one year6(65,524)-
Net current assets (liabilities)23,322100
Total assets less current liabilities32,187100
Creditors amounts falling due after one year7(66,400)-
Net assets(34,213)100
Capital and reserves
Called up share capital100100
Profit and loss account(34,313)-
Shareholders' funds(34,213)100
The financial statements were approved and authorised for issue by the Board of Directors on 10 December 2024, and are signed on its behalf by:
GILLANI, Kubra
Director
Registered Company No. 14327842
EPHARMA LIMITED
Notes to the Financial Statements
for the year ended 31 August 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Straight line (years)
Fixtures and fittings7
Vehicles5
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
2.Average number of employees

20242023
Average number of employees during the year80
3.Tangible fixed assets

Vehicles

Fixtures & fittings

Total

£££
Cost or valuation
Additions1,2758,0589,333
At 31 August 241,2758,0589,333
Depreciation and impairment
Charge for year213255468
At 31 August 24213255468
Net book value
At 31 August 241,0627,8038,865
At 31 August 23---
4.Stocks

2024

2023

££
Raw materials and consumables12,115-
Total12,115-
5.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables44,243-
Other debtors7,879-
Total52,122-
6.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables59,787-
Taxation and social security691-
Other creditors5,046-
Total65,524-
7.Creditors: amounts due after one year

2024

2023

££
Other creditors66,400-
Total66,400-